Davis C. Ryman

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 130 citations · Full text

Clinical Trials, Progressive Supranuclear Palsy, Placebo-controlled Trial +7

Factors Associated With the Onset and Persistence of Post–Lumbar Puncture Headache

Andrés E. Monserrate, Davis C. Ryman, Sheng‐mei Ma et al. · JAMA Neurology · 2015 · 92 citations · Full text

Prader–Willi-Like Phenotype Caused by an Atypical 15q11.2 Microdeletion

Qiming Tan, Kathryn J. Potter, Lisa C. Burnett et al. · Genes · 2020 · 44 citations · Full text

Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial

Elizabeth Roof, Cheri Deal, Shawn E. McCandless et al. · The Journal of Clinical Endocrinology & Metabolism · 2023 · 43 citations · Full text

Genetic loci modulating amyloid-beta levels in a mouse model of Alzheimer's disease

Davis C. Ryman, Yuan Gao, Bruce T. Lamb · Neurobiology of Aging · 2007 · 40 citations · Full text

Alzheimer's Disease, Amyloid-beta Levels, Dementia +11